Enhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Read moreIt has been presented a chemical modification of thermoplastic polyurethane (TPU) with an antimicrobial protein that reduces the formation of biofilms of multidrug-resistant bacteria, in biomedical de...
Read moreNew research study, published in the Journal of Virology, has resolved the crystal structure of a key protein found in the saliva of the Aedes aegypti mosquito.
Read moreThe OTC supplements landscape of 2025 shows a health approach that’s both personal and proactive. We’ve seen how personalized formulations now match your unique body needs, while plant-based optio...
Read moreThe phase 3 clinical trial KEYNOTE-689 shows that incorporating the monoclonal antibody pembrolizumab before and after surgery, alongside standard of care, improves event-free survival in patients wit...
Read moreInvestigadores de la UPM desarrollan con médicos del Hospital 12 de Octubre una plataforma para el diagnóstico precoz de cardiotoxicidad en pacientes oncológicos
Read moreEl estudio ha identificado con una elevada sensibilidad la enfermedad mínima residual tras la cirugía, anticipando qué pacientes recaerán y quiénes podrán evitar tratamientos innecesarios
Read moreThe study, with the participation of Joan XXIII University Hospital and CIBER, analyzes 103 patients and highlights the relationship between hypertension and unfavorable disease progression
Read moreNew studies emphasize how peptide-based launchers, the core of Gate2Brain‘s technological platform, are poised to revolutionize drug delivery across the blood-brain barrier.
Read moreIt has been shown that the brain, and more specifically certain hypothalamic neurons, is capable of modifying the composition of the intestinal microbiota in mice; and it can do so in a matter of hour...
Read moreIt has been developed an innovative CAR-T cell therapy targeting the CD30 protein (HSP-CAR30), which has shown high efficacy in patients with refractory CD30+ lymphoma
Read moreLa Fundación CRIS contra el cáncer ha otorgado dos becas de excelencia a investigadoras del Clínic Barcelona-IDIBAPS, con una dotación total de 680.000 euros.
Read more